Forbes September 13, 2020
Two years ago, the news of the birth of twins in China whose embryonic DNA were modified by a scientist to prevent HIV infection, snowballed a worldwide discourse around the ethics of using DNA modifying technologies. Many governments rushed to legislate prohibitions on germline gene editing, which involve genetic changes that can be passed onto future generations, while still allowing for applications that can treat a specific disease within an individual. But it wasn’t until earlier this month that an international consortium released new guidelines on how to proceed.
The stakes were high, since Crispr, which can target and cut sections of DNA like a pair of molecular scissors, has myriad applications for medicines and other advancements. The International...
Today's Sponsors
Today's Sponsor